<DOC>
	<DOCNO>NCT03027336</DOCNO>
	<brief_summary>The overall objective study assess efficacy Coleosoma formulation ( ferment red rice , berberine chitosan ) reduce non-HDL cholesterol dyslipidemic patient .</brief_summary>
	<brief_title>Efficacy Tolerability Nutraceutical Formulation Coleosoma Dyslipidemic Subjects</brief_title>
	<detailed_description>The incidence cardiovascular disease relate atherosclerosis lead cause death industrialized country many develop country . It become , therefore , essential implement preventive strategy lifestyle change order prevent / control risk factor relate cardiovascular disease . Dyslipidemia characterize qualitative quantitative alteration plasma lipid lipoprotein . In subject yet indicate statin therapy , guideline recommend lifestyle ( diet exercise ) act control cardiovascular risk factor . The formulation Coleosoma supplement compose ferment red rice , berberine chitosan . Aim study evaluate effectiveness coleosoma formulation reduce non-HDL cholesterol ( Non-HDL-C ) , provide measure cholesterol content atherogenic particle . This single-center , randomize ( 3:1 ) control double-blind phase II study involve dyslipidemic patient non-HDL cholesterol level ≥ 160 mg / dl . The study include maximum 4 visit subject enrol . All eligible patient V0 ( screen ) undergo baseline assessment ( V1 ) allocate accord procedure randomization one study arm . Follow-up ( FU ) visit subject 4 ( V2 ) 12 week ( V3 ) randomization . Laboratory diagnostic : At visit patient undergo : anthropometric hemodynamic assessment : weight height Body Mass Index ( BMI ) calculation , waist circumference , blood pressure , heart rate ; blood collection metabolic/hormonal profile : fasting plasma glucose , HbA1c , insulin , glucagon , active glucagon-like peptide-1 ( GLP-1 ) , total gastric inhibitory polypeptide ( GIP ) , total cholesterol , HDL-cholesterol , triglyceride , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , creatinine , creatine phosphokinase ( CPK ) , apolipoprotein ( Apo ) B , Apo A1 , inflammatory cytokine ( IL-1 , IL-6 , IL-10 , high-sensitivity C Reactive Protein ( hsPCR ) , TNFalpha ) . At V1 V2 Endothelial Progenitor Cells ( EPC ) number evaluate cytofluorimetric assay . Safety analysis conduct 12 week treatment determine ALT , CPK estimate Glomerular filtration rate ( eGFR ) value . This study sponsor DOC generici s.r.l .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>nonHDL cholesterol ≥ 160 mg/dl ; provide write Informed Consent ; capable understanding nature , purpose study procedure diabetes ( ADA criterion ) reduce renal ( GFR &lt; 60 mL/min/1.73m2 ) hepatic ( transaminase level &gt; 2.5 fold upper reference limit ) function ; present past history alcohol drug abuse cerebrovascular neoplastic disease 5 year prior study visit use drug food supplement interfere cholesterol level pregnancy breastfeeding ; monogenic dyslipidemia ; participation clinical trial previous 30 day ; uncompensated hypothyroidism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>dyslipidemia</keyword>
	<keyword>dietary supplement</keyword>
</DOC>